Graft versus host disease (GVHD) Treatment and Growth Analysis with 2.90% by 2023

    99
    0
    SHARE
    Allergic Conjunctivitis

    DelveInsight’s “Graft Versus Host Disease (GVHD) -Epidemiology Insights -2023” Report provides an overview of the disease GVHD for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) from 2013-2023.
    GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD happens when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them. The disease is divided into two sub-types, acute GVHD which occurs usually in the initial 2-3 months after transplantation, and chronic GVHD that occurs after 3-4 months after transplantation and has more diverse complications. Although being used as a preventive therapy rather than treatment, Temcell-HS is currently the only therapy available for GVHD. It is marketed in Canada, Japan and Netherlands. According to DelveInsight, the total number of HSCTs and number of incident cases for first HSCTs is expected to grow at a CAGR of 2.80% and 2.90% respectively for the period 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Scope of the Report
    • The Report includes the prevalent population and how will it change over the next eight years.
    • Prevalent or incident cases segmented by age and sex.
    • Coverage of key Graft versus host disease (GVHD) subpopulations and its prevalent or incident cases
    • The key differences in epidemiology patterns across the seven market segments

    Key Coverage and Benefits

    • The report will help in developing business strategies by understanding the trends shaping and driving the global Graft versus host disease (GVHD) market.
    • Identifying prevalent patient populations as well as risk factors in the global Graft versus host disease (GVHD) market will help to improve product design, pricing, and launch plans.
    • Organize sales and marketing efforts by identifying the best opportunities for Graft versus host disease (GVHD) therapeutics in each

    Request for a Demo or Sample Copy of Report at: https://www.diligentmarket.com/request-sample-page.php?gturl=13768

    Scope of this report: The report provides competitive Epidemiology landscape of Graft versus host disease (GVHD). The report provides the marketed drugs information including its sales, development activities and details of patent expiry. The report provides the insight of current and future market for Graft versus host disease (GVHD). The report provides Epidemiology products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information. Coverage of the Graft versus host disease (GVHD) Epidemiology on the basis of target, MOA, route of administration, technology involved and molecule type. The report reviews key players involved in the therapeutics development for Graft versus host disease (GVHD) and also provide company profiling. The report also gives the information of dormant Epidemiology projects. Epidemiology products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages and Provides Epidemiology assessment by monotherapy and combination therapy products, stage of development and molecule type.

    Tables of Content

    Graft Versus Host Disease (GVHD) Overview
    • Disease Definition
    • Disease Types
    • Acute GvHD
    • Chronic GvHD
    • Grades of GvHD
    • Pathophysiology
    • Risk Factors for GVHD
    • Diagnosis
    2. Epidemiology and Patient Population
    • Key Points
    3. UNITED STATES
    • Assumptions and Rationale
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
    4. EUROPE
    • Assumptions and Rationale
    4.1 Germany
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
    4.2 France
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
    4.3 Spain
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
    4.4 Italy
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
    4.5 United Kingdom
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
    5. JAPAN
    • Assumptions and Rationale
    • Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
    • Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
    • Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
    6. Appendix
    7. Report Methodology
    8. Consulting Services
    9. Disclaimer
    10. About DelveInsight

    Browse Full Report at: https://www.diligentmarket.com/graft-versus-host-disease-gvhd-epidemiology-forecast-to-2023-13768-p.php

    About us:

    DiligentMarket is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

    We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharmaand Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.

    The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing cutting-edge market and Epidemiology information, to our clients.

    Connect With us on:

    +91-750 707 8687

    sales@diligentmarket.com

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here